304am永利集团|·主頁(歡迎您)

Be the most trusted biotech company

2021-09-17

The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for First-Line Treatment of sqNSCLC Accepted by China's NMPA, Phase 3 MRCT Met its Primary Endpoint
2021-08-18

Henlius reports half-year (H1) 2021 results, outlines remarkable growth in commercialization and needs-driven innovation
2021-08-05

Henlius Entered into a Collaboration with Promega to Develop the Companion Diagnostic Kit for Henlius' Serplulimab MSI-H Solid Tumours Indication
2021-07-19

First Patient Dosed in Phase 1 Clinical Trial of Henlius Bevacizumab HLX04-O
2021-06-11

Clinical Results of Henlius HLX04, a Bevacizumab Biosimilar, Published in International Well-known Journals
2021-06-07

Henlius Has Released Two Clinical Studies of Anti-PD-1 mAb Serplulimab for the First Time at 2021 ASCO Annual Meeting
2021-06-01

Henlius Received IND Approval for Its Novel Anti-CD73 mAb HLX23 from US FDA
2021-05-21

Phase 3 Clinical Results of Rituximab Injection in RA Patients Was First Released at the 25th National Congress of Chinese Rheumatology Association
2021-05-14

Henlius Wins"Most Innovative Global Biopharmaceutical Company 2021"Hosted by GHP Magazine

1
2
3
4
5